Suppr超能文献

ARID1A缺陷型卵巢透明细胞癌细胞的蛋白质组学分析揭示了线粒体电子传递链亚基丰度的差异以及可靶向的线粒体途径。

Proteomic Analysis of ARID1A-Deficient Ovarian Clear Cell Carcinoma Cells Reveals Differential Mitochondria ETC Subunit Abundances and Targetable Mitochondrial Pathways.

作者信息

Perez Jesenia M, Ryu Joohyun, Khan Hannah, Shetty Mihir, Parker Emma, D'Arcy Padraig, Zhu Shijia, Bazzaro Martina, Thomas Stefani N

机构信息

Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA.

Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA.

出版信息

Int J Mol Sci. 2025 Jun 7;26(12):5466. doi: 10.3390/ijms26125466.

Abstract

ARID1A-deficient ovarian clear cell carcinoma is a highly lethal gynecologic cancer that depends heavily on mitochondrial respiration. Our biochemical and proteomic analyses reveal that ARID1A knockout cells exhibit marked upregulation of specific subunits within mitochondrial electron transport chain (ETC) Complexes I, III, and IV. However, this upregulation does not directly translate into increased sensitivity to broad-spectrum inhibitors targeting these complexes. These findings suggest that broad-spectrum mitochondrial inhibitors may not be effective therapeutic options for ARID1A-deficient cancers. Instead, the selective inhibition of specific ETC subunits may offer a more promising approach to exploit the metabolic vulnerabilities of ARID1A-deficient cells.

摘要

缺乏ARID1A的卵巢透明细胞癌是一种高度致命的妇科癌症,严重依赖线粒体呼吸作用。我们的生化和蛋白质组学分析表明,敲除ARID1A的细胞中线粒体电子传递链(ETC)复合体I、III和IV中的特定亚基显著上调。然而,这种上调并没有直接转化为对靶向这些复合体的广谱抑制剂的敏感性增加。这些发现表明,广谱线粒体抑制剂可能不是治疗缺乏ARID1A的癌症的有效选择。相反,选择性抑制特定的ETC亚基可能为利用缺乏ARID1A的细胞的代谢弱点提供一种更有前景的方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验